Wegovy reduces knee pain in osteoarthritis patients with obesity, study finds

Semaglutide, better known as Ozempic and Wegovy, helped alleviate pain from knee osteoarthritis and improve function in patients with severe obesity, a new study found.

The results of the 68-week trial were published in the New England Journal of Medicine, and could pave the way for a future FDA approval of GLP-1 receptor agonists for the joint-degrading condition.

GLP-1 drugs have revolutionized obesity treatment, but research suggests they could also help treat conditions as varied as heart disease, addiction and sleep apnea. Novo Nordisk, the maker of Wegovy, may have funded the latest trial to see if knee osteoarthritis might be added to that growing list of non-obesity indications — and help the drug get broader insurance coverage.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Employees with obesity may have lower work productivity compared to people with normal weight

People with obesity may have lower work productivity due to increased risk of illness, contributing to increased costs for employers, according to industry-supported research being

June 18, 2023

Smileyscope Receives FDA Clearance for First-Ever VR Analgesic

What You Should Know: – Smileyscope™, a pioneer in virtual reality (VR) therapeutic solutions, has received Class II clearance from the U.S. Food and Drug

December 9, 2023

Sound business performance in first nine months of 2023 – Biotech Investments

EQS-News: Asklepios Kliniken / Key word(s): 9 Month figures/Financing Asklepios Group: Sound business performance in first nine months of 2023 23.11.2023 / 10:00 CET/CEST The

November 24, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.